GLP-1/Weight Loss

With backing from GV and Dexcom, Signos is using AI and OTC glucose monitors to offer a new path for sustainable weight management beyond GLP-1 drugs.

New preclinical data shows RTY-406 could be a first-in-class therapy for PSC, a progressive liver disease with no effective treatments.

Wellness brand Le-Vel is launching a telehealth service for prescription peptides, blurring the lines between direct sales and mainstream medicine.

Vanda Pharmaceuticals' rare disease drug gets a key designation in Japan, unlocking major incentives and promising a new treatment for a severe skin disease.

A new analysis reveals most insured Americans can't access obesity drugs, even with coverage, due to restrictive insurance hurdles.

MBX Biosciences prepares for the Jefferies conference, with investors eyeing updates on its late-stage hypoparathyroidism drug and promising obesity portfolio.

A $182,500 seizure in Quebec is just the tip of the iceberg, revealing a nationwide struggle against high-tech smuggling, drones, and prison violence.

With final court approval, Crescita Therapeutics will be delisted from the TSX as global platform ClinActiv snaps up its dermatology assets.

Ozari Health launches a nationwide service for affordable compounded semaglutide, navigating a complex and increasingly regulated market for GLP-1 drugs.

Strong glaucoma sales and disciplined spending helped Iridex narrow its quarterly loss, signaling resilience despite retina segment woes and global headwinds.

A $290M war chest fuels a new public biotech aiming to help millions of migraine patients who don't respond to current blockbuster therapies.

Mineralys Therapeutics' lorundrostat shows promise for millions with uncontrolled blood pressure and kidney disease, targeting a key hormonal driver.

A new bispecific antibody, TRIV-573, enters clinical trials, targeting both skin barrier and inflammation to redefine atopic dermatitis therapy.

With 12% weight loss in a pivotal trial, Vincentage Pharma's VCT220 pill is set to challenge injectables and reshape China's obesity drug market.

The Aesthetic Syndicate evolves into Manor, launching a national brand that fuses injectables with medically supervised GLP-1 therapy and holistic health.

The insurer is offering at-home defibrillators and health tech, aiming to redefine its role from covering death to extending life. But what does it mean for you?

European digital health firm Apomeds launches in the UK, targeting the booming telehealth market with a focus on discreet, high-demand treatments.

Biocon merges its biosimilar and generics units, appointing 30-year veteran Shreehas Tambe as CEO to forge a new globally-scaled biopharma enterprise.

Telehealth platforms like ReflexMD offer cheaper, compounded GLP-1s for weight loss. But what are the risks, and what do consumers need to know?

As its new obesity drug enters a key trial, Biohaven bets on a novel approach: reducing fat while preserving precious muscle mass. Can it redefine weight loss?